Ambu A S Ord (AMBFF) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ambu A/s Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.138 Hello, everyone, and welcome to this conference call presenting 00:00:05.138 -- 00:00:10.545 our Q4 and full year results from 2024-25 for 00:00:10.545 -- 00:00:12.545 Ambu. 00:00:12.647 -- 00:00:15.792 My name is Britt Milby Jensen. I'm the CEO of Ambu. 00:00:15.792 -- 00:00:21.239 And with me today, I have Henrik Skagbender, our Chief Financial Officer. 00:00:21.239 -- 00:00:24.480 So let's get going. 00:00:25.259 -- 00:00:29.669 So we'll start with the highlights from the year that we just exited. 00:00:29.669 -- 00:00:34.720 And overall, we delivered a very strong organic revenue growth of 00:00:34.720 -- 00:00:36.720 13.1%. 00:00:37.426 -- 00:00:42.573 And if we look at our endoscopy business, that grew for the year 15.4%. 00:00:43.079 -- 00:00:48.130 This underscores the continued momentum and potential of 00:00:48.130 -- 00:00:53.280 moving patients from using reusable endoscopes 00:00:53.280 -- 00:00:56.206 to single-use endoscopes. 00:00:56.206 -- 00:01:02.615 If we look at our margins, we delivered a margin of 13 And this 00:01:02.897 -- 00:01:08.202 is impacted positively by our operational leverage, where we continue to 00:01:08.202 -- 00:01:13.207 drive scale and be more efficient. And then on the other side, we also, given 00:01:13.207 -- 00:01:18.311 we are a growth company, as the most important, we are, as we have 00:01:18.311 -- 00:01:23.656 previously communicated, continuing to invest in commercial resources 00:01:23.656 -- 00:01:28.118 and scale in order to continue to deliver that growth. 00:01:28.118 -- 00:01:33.203 At the same time, we had two external factors, and Henrik will come back to that in 00:01:33.203 -- 00:01:38.908 terms of FX and tariffs that had a negative impact on the results. 00:01:38.908 -- ...